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Introduction: For lung squamous cell carcinomas, there are no path-
ological findings that have been universally accepted as prognostic 
factors, with the exception of pathological stage. Tumor budding and 
nuclear grade have been recognized as a poor prognostic factor in 
other carcinomas. In this study, we investigated whether pathological 
findings could determine prognosis in lung squamous cell carcinomas.
Methods: All available tumor slides from patients with surgically 
resected, solitary lung squamous cell carcinomas (1999–2009) were 
reviewed (n = 485; stage I/II/III, 281/136/68). Tumors were evaluated 
for differentiation, subtypes (keratinizing, nonkeratinizing, basaloid 
pattern, papillary growth, and clear cell feature), tumor nest size 
(tumor budding and single cell invasion), and nuclear grade (nuclear 
diameter and mitosis). Overall survival (OS) was estimated using the 
Kaplan-Meier method (stratified by pathological stage), and group 
differences were investigated using the stratified log-rank test and the 
Cox proportional hazards model.
Results: OS was significantly decreased in patients with versus with-
out single cell invasion (p = 0.002 for the entire tumor and p = 0.001 
for tumor edge), with large versus small nuclei (p = 0.011), and with 
high versus low grade tumor budding (p < 0.001 for maximum and 
p = 0.007 for total). In multivariate analyses, single cell invasion (haz-
ard ratio [HR], 1.47–1.49), nuclear diameter (HR, 1.09–1.33), and 
tumor budding (HR, 1.04) were independent prognostic factors of OS. 
However, histologic subtyping including keratinizing, nonkeratinizing, 
basaloid, and clear cell subtypes did not show prognostic significance.
Conclusions: Pathological factors can help stratify prognosis in 
patients with lung squamous cell carcinomas.
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Currently, the tumor, node, metastasis (TNM) stage rather than any specific histologic feature is the most reli-
able prognostic predictor of non–small-cell lung cancers.1 
However, recently for lung adenocarcinoma, in addition to the 
TNM staging, the new international multidisciplinary histo-
logic classification proposed by the International Association 
for the Study of Lung Cancer (IASLC), American Thoracic 
Society (ATS), and European Respiratory Society (ERS) in 
20112 has led to identification of the prognostic significance of 
the predominant histological patterns, and this has been vali-
dated in separate, large cohort studies (>400 patients) across 
multiple countries.3–6 Traditionally, lung squamous cell carci-
nomas have been graded by the degree of keratinization (well, 
moderately, and poorly differentiated tumors). In the current 
World Health Organization (WHO) classification of lung car-
cinomas, squamous cell carcinomas are classified into papil-
lary, clear cell, small cell, and basaloid subtypes; nevertheless, 
these have not been shown to have prognostic or other clinical 
significance.7 Furthermore, no alternative histologic features 
or grading system have been identified that clinicians could 
use to predict patient clinical outcome.
Because histologic subtyping of lung squamous cell car-
cinoma has not proven to be associated with survival, we con-
sidered evaluating two approaches to assessment of patterns of 
tumor invasion: single cell invasion and tumor budding, which 
have been demonstrated to have prognostic significance in sev-
eral types of cancers. One initial study identified single cell 
invasion as an unfavorable prognostic indicator in patients with 
lung squamous cell carcinomas.8 Tumor budding is defined as 
the presence of isolated small tumor nests composed of less 
than five tumor cells in the stroma of the invasive tumor edge 
and it corresponds to significant tumor invasiveness.9,10 It has 
been shown to correlate with an unfavorable clinical outcome 
(i.e., patient survival and disease recurrence) in colorectal can-
cer.9,10 Interestingly enough, tumor budding may also exhibit 
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the process of epithelial mesenchymal transition, which regu-
lates the epithelial tumor cells transformation into the mesen-
chymal phenotype, thus increasing the capacity of migration 
and invasion.11–13 In addition to tumor budding, the size of the 
tumor nests (tumor clusters composed of ≤15 tumor cells) was 
determined to be a poor prognostic factor for the histological 
risk grading system of head and neck squamous cell carcino-
mas.14,15 Despite the aforementioned correlations, comprehen-
sive analyses on the prognostic value of tumor budding and 
tumor nest size have not been performed using a large cohort 
of resected lung squamous cell carcinomas.
A universally recognized histologic grading system for 
lung cancer has not been established. The clinical utility of 
using a nuclear grading system (e.g. mitotic count and nuclear 
atypia) has already been established in other major cancers 
such as breast carcinoma.16,17 For lung adenocarcinoma, data 
are emerging for architectural and nuclear grading approaches 
that hopefully will lead to a uniform grading system in the 
near future.18–20 After evaluating all of the nuclear features in 
stage I lung adenocarcinomas, our group has recently deter-
mined that a higher mitotic count is an independent predictor 
of a higher risk of recurrence. We then proposed a new grad-
ing system that combined architectural features (2011 IASLC/
ATS/ERS classification) and nuclear grade (mitotic count).21 
However, for lung squamous cell carcinoma, a grading system 
for the prediction of patient’s outcomes has not been rigor-
ously investigated.
In this study of a large series of patients with resected 
lung squamous cell carcinomas, we performed comprehensive 
analyses of pathological factors (tumor differentiation, histo-
logic subtype, tumor budding, tumor nest size, and nuclear 
grade). We investigated whether any of the pathological fac-
tors correlated with clinical outcomes (overall survival [OS] 
and disease recurrence), independent of pathological stage.
MATERIALS AND METHODS
Patients
This retrospective study was approved by the 
Institutional Review Board of Memorial Sloan-Kettering 
Cancer Center (MSKCC). We reviewed all patients with soli-
tary lung squamous cell carcinoma who underwent surgical 
resection at MSKCC between 1999 and 2009; tumor slides 
were available for histologic evaluation from 485 of those 
patients. Clinical data were collected from the prospectively 
maintained Thoracic Surgery Service lung carcinoma data-
base, and disease stage was assigned on the basis of the 7th 
edition of the American Joint Committee on Cancer TNM 
Staging Manual.22 On chest computed tomography (CT), the 
tumor locations were divided into two categories: “peripheral 
lesion” when located within the outer third ellipse, and “non-
peripheral lesion” when located within the middle third (inter-
mediate lesion) or within the inner third (central lesion).23,24
Histologic Evaluation
All available hematoxylin and eosin (H&E) stained 
slides were reviewed by two pathologists (K.K. and W.D.T.) 
using an Olympus BX51 microscope (Olympus, Tokyo, Japan) 
with a standard 22-mm diameter eyepiece. Both pathologists 
had no knowledge of those patients’ clinical outcomes.
Tumors were graded by a degree of squamous differ-
entiation into well, moderately, and poorly differentiated, in 
accordance with the 2004 WHO classification of lung carcino-
mas.7 In the well-differentiated tumors, there were tumor nests 
composed of differentiated keratinocyte-like tumor cells with 
prominent keratinization (layered and cytoplasmic keratin) 
and intercellular bridges. In the poorly differentiated tumors, 
squamous structure was only noticeable in a small area of the 
tumor. The moderately differentiated tumors showed an inter-
mediate degree of squamous differentiation that was between 
well and poorly differentiated tumors.
Histologic subtyping was performed in a similar 
fashion to nasopharyngeal carcinomas in the 2005 WHO 
Classification, Pathology and genetics of Head and Neck 
Tumours; they were classified as nonkeratinizing, keratinizing, 
and basaloid squamous cell carcinomas.25 The percentage of 
keratinizing pattern, including layered (Fig. 1A) and cytoplas-
mic keratinization (Fig. 1B), was recorded, and then tumors 
were classified as having a keratinizing subtype when there 
was greater than or equal to 5% keratinizing pattern of the 
entire tumor whereas nonkeratinizing subtypes were defined 
as having less than 5% keratinizing pattern (Fig. 1C). The 
basaloid pattern was defined as tumor nests showing promi-
nent peripheral palisading of tumor cells with scanty cyto-
plasm (high nuclear/cytoplasmic ratio) and a greater amount 
of hyperchromatic nuclei (Fig. 1D).7 The percentage of basa-
loid pattern was recorded and then the tumors were classified 
as having a basaloid subtype if there was greater than 50% 
basaloid pattern as previously recommended.26,27 The percent-
age of papillary growth was recorded in 5% increments. Clear 
FIGURE 1.  Histologic subtypes (hematoxylin and eosin-
stain; original magnification, x200: A–D). A, keratinizing 
subtype with layered keratin. (B) Keratinizing subtype with 
cytoplasmic keratinization. (C) Nonkeratinizing subtype. (D) 
Basaloid subtype.
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cell features were defined as tumor cells with clear cytoplasm 
and were recorded in 5% increments; it was considered pres-
ent when ≥5% of the tumor cells had a clear cell pattern. No 
cases were classified as the small cell variant of squamous 
cell carcinoma, although occasional basaloid carcinomas had 
tumor cells that resembled small cell carcinoma.
After scanning through the entire set of tumor slides at 
intermediate-power fields at ×100 magnification, tumor bud-
ding and the size of the smallest tumor nest were assessed at 
the most invasive area with the maximal number of the smallest 
tumor nests. Tumor budding was defined as small tumor nests 
composed of less than five tumor cells (Fig. 2A, B), and they 
were counted in 10 high-power fields (HPFs) at ×200 magni-
fication.9 According to the number of tumor budding counted 
in 10 HPFs, tumor budding was assessed two ways: (1) the 
maximum number of tumor budding per HPF among the 10 
HPFs (maximum budding/one HPF) and (2) the total num-
ber of tumor budding of 10 HPFs (total budding/10 HPFs). 
Based on the approach of previously published studies analyz-
ing the prognostic significance of the tumor nest size assessed 
by the number of tumor cells,8,10,14,15 the size of the smallest 
invasive tumor nest was classified into large nest (composed 
of >15 tumor cells), intermediate nest (five to 15 tumor cells), 
small nest (two to four tumor cells), and single cell invasion 
(Fig. 2C). The size of the smallest tumor nest was assessed two 
ways: (1) the tumor nests in entire tumor area and (2) the tumor 
nests infiltrating the tumor edge on the outside the tumor.
The percentages of tumor necrosis and fibrosis were 
recorded. Tumor necrosis was considered present when there 
was greater than or equal to 10% necrosis in the entire tumor.28 
When there was greater than or equal to 50% fibrosis in the entire 
tumor, it was considered severe.29 In addition, pleural invasion, 
which was classified as absent (PL0) or present (PL1, PL2, and 
PL3),22 and lymphovascular invasion were investigated.
The nuclear features were evaluated according to the 
methodologies used in our previous publications.21,30 They 
were assessed using a HPF at ×400 magnification (0.237 mm2 
field of view) at the region of the tumor with the greatest abnor-
mal nuclear features. This was done after scanning through the 
entire set of tumor slides at intermediate-power fields at ×100 
magnification. For nuclear diameter, we selected at least three 
HPFs with the largest nuclei and then calculated the aver-
age nuclear diameter of at least 100 tumor cells using nearby 
small lymphocytes (≈4.0 μm) as reference.19 Nuclear atypia 
was recorded in the area of the tumor with the highest degree 
of atypia; at least 5% of the entire tumor area needed to be 
affected. The degree of atypia was assessed using the follow-
ing gradation: mild atypia—uniform nuclei in size and shape; 
moderate atypia—nuclei in intermediate size with slight 
irregularity in shape; and severe atypia—enlarged nuclei of 
varied sizes and irregular contours with some nuclei at least 
twice as large as others. The nuclear/cytoplasmic (N/C) ratio 
was broken down into the following three categories: low 
N/C ratio (<1/3 nucleus to cytoplasm area), intermediate N/C 
ratio (1/3–2/3), and high N/C ratio (>2/3). Chromatin pattern 
was differentiated using two distinctions, finely granular and 
coarsely granular. The prominence of nucleoli was also bro-
ken down into two distinct categories: indistinct—inconspic-
uous at intermediate—power fields at ×100 magnifications, 
and distinct—conspicuous at intermediate—power fields. 
Intranuclear inclusions were determined as present or absent 
in an examination of 50 HPFs. Mitoses were evaluated in the 
50 HPF areas that contained the highest mitotic activity and 
then were calculated as an average of mitotic figures per 10 
HPFs (2.37 mm2 area).21,30 Atypical mitoses were considered 
present if any were observed after examination of 50 HPF.21,30
Tissue Microarray
Formalin-fixed, paraffin-embedded tumor specimens 
were used for tissue microarray construction. We marked three 
representative tumor areas on H&E-stained slides, and using 
an automated tissue arrayer ATA-27 (Beecher Instruments, 
Sun Prairie, WI), we arrayed cylindrical 0.6-mm tissue cores 
from the corresponding paraffin blocks into a recipient block; 
this resulted in five tissue microarray blocks. In total, there 
were 447 available cases with adequate cores for immunohis-
tochemical analysis.
Immunohistochemistry and Scoring of Ki-67
We took 4-mm sections from the tissue microarray blocks 
and briefly deparaffinized them in xylene and dehydrated them 
in graded alcohols. The standard avidin-biotin complex perox-
idase technique was used for immunohistochemical stains of 
anti-Ki-67 antibodies (clone MIB-1, Immunotech, Westbrook, 
ME; diluted at 1:100). Sections were stained using a Ventana 
Discovery XT Automated Immunohistochemical Stainer 
(Ventana, Tucson, AZ) according to the manufacturer’s guide-
lines. Diaminobenzidine was used as the chromogen, and 
FIGURE 2.  Tumor budding and single cell invasion (hema-
toxylin and eosin-stain; original magnification, ×40: A, ×400: 
C–D). A, Tumor budding identified in invasive tumor edge. 
(B) Higher magnification of a square box in the Figure 3A 
showing tumor budding composed of less than five tumor 
cells (arrows). (C) Single cell invasion of tumor cells in stroma 
(arrows). (D) Large nuclei defined as greater than four small 
lymphocytes in diameter.
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hematoxylin was used as the nuclear counterstain. Positive 
control tissues were stained in parallel with the study cases. 
The Ki-67 proliferation index was recorded as the percent-
age of tumor cells with nuclear positive immunostaining in 
each tissue microarray core. The average percentage of the 
tumor cores was used as the Ki-67 proliferation index for each 
patient.21,30 Immunohistochemical studies performed to con-
firm squamous differentiation are being reported elsewhere.31
Statistical Analysis
Associations between variables were analyzed using the 
χ2 test (used for categorical variables) and the two-sample t 
test (used for continuous variables). To dichotomize the con-
tinuous pathological variables (tumor budding, tumor nest 
size, mitotic count, and Ki-67 index) into high/low categories, 
we applied the method of optimal cut-point estimation, which 
uses a maximally selected log-rank statistic to choose the cut-
point that best stratifies the cohort.32
Two endpoints were investigated; OS in patients with 
all stages and cumulative incidence of recurrence (CIR) 
in patients with stage I diseases. OS was estimated by the 
Kaplan-Meier method, and associations between factors and 
survival were analyzed using the log-rank test, stratified by 
pathologic stage. For those variables dichotomized by using 
the optimal cut-point method, p values were adjusted for opti-
mal search.32 OS was defined as the time from surgery to death 
or the last follow-up. Multivariate analyses were performed 
using the Cox proportional hazards regression model.
The associations between factors and the risk of recur-
rence were evaluated with competing risks analyses.33,34 The 
risk of recurrence (or CIR) was estimated using a cumulative 
incidence function that accounted for death without recur-
rence as a competing event. Patients were censored if they 
were alive and without a documented recurrence at the time of 
their most recent follow-up. The differences in CIR between 
groups were assessed using the methods of gray (univariate 
nonparametric analyses) and the Fine and gray model for 
competing risks (multivariate analysis).35
For each of the two outcomes, multivariate models 
were built to include all significant factors in the univariate 
analyses. Any associations between pathologic factors were 
checked, and if there were any strong associations discovered, 
only one factor was included into the model at any given time. 
All statistical tests were two-sided and used a 5% significance 
level. Statistical analyses were performed using R (version 
3.0.1; R Development Core Team) with the “maxstat,” “sur-
vival,” and “cmprsk” packages.
RESULTS
Patient Clinical Characteristics and 
Their Associations with OS and CIR
The median age in this 485 patient cohort was 71 years 
(range, 39–88 years). Most patients had pathological stage I dis-
ease (58%), whereas a smaller percentage of patients presented 
with stage II (28%) and stage III (14%) pathological disease. 
With regard to surgical procedure, 83% underwent lobectomies 
and 17% underwent limited resections (segmentectomy [n = 35] 
and wedge resection [n = 47]). Among patients undergoing lim-
ited resections, most patients were classified as stage I (n = 68) 
whereas a smaller number of patients were classified as stage II 
(n = 7) and stage III (n = 7). Among the limited resection group, 
most patients (n = 60) underwent lymph node sampling or dis-
section; the remaining patients (n = 22) were staged by chest 
CT and/or positron emission tomography (PET) scans only, and 
all of them were classified as stage I disease. Almost one-fifth 
(19%) of patients received adjuvant therapy. Among the patients 
whose chest CT scans were available (n = 423), 233 (55%) were 
classified as peripheral lesion. Perhaps, as the period of cases 
included in this study spanned only the most recent decade, we 
did not have the opportunity to see a significant shift from central 
to peripheral predominant location. We also did not find signifi-
cant clinical associations with central versus peripheral location. 
During the study period, 29% of patients (n = 139) experienced 
a recurrence and 58% (n = 281) died from both related and unre-
lated causes. The median follow-up period for all patients was 4.1 
years (range, 0.01–13 years) and the 5-year patient OS was 59%.
The associations between the clinical characteristics of 
patients and OS/CIR were summarized in Table 1. Regarding 
pathological stage, the 5-year OS was the worst for patients with 
stage III disease, followed by patients with stage II disease, and 
finally those with stage I disease (40%, 51%, and 67%, respec-
tively; p < 0.001; Fig. 3A). In the analysis of OS stratified by 
pathological stage, older age (>65 years old; p < 0.001), the male 
sex (p = 0.049), a history of heavy smoking (>90 smoking pack-
year; p = 0.011), limited resection (p = 0.016), and undergoing 
adjuvant therapy (p = 0.029) were all associated with a worse OS 
(Table 1A). In the CIR analysis of stage I disease, the male sex 
(p = 0.008) and a higher T classification (T2 vs. T1; p = 0.029) 
were associated with an increased risk of recurrence (Table 1B).
Histological and Nuclear Features 
and Their Associations with OS
The associations between the histological and nuclear fea-
tures and OS were summarized in Tables 2A and3A. With regard 
to histologic subtyping, a major finding was the lack of prognostic 
significance for presence of keratinization (p = 0.97, keratinizing 
versus nonkeratinizing) and clear cell (p = 0.23) features. Patients 
with a basaloid subtype tumor had a slightly better 5-year OS 
than those with nonbasaloid tumors (69% versus 58%). However, 
this finding was not statistically significant after we stratified the 
patients by pathological stage (p = 0.071). Clear cell and papil-
lary features were infrequent. Although clear cell features were 
identified in 61 (13%) cases, there were only three cases that 
showed predominant clear cell features (>50%). Although focal 
papillary growth (usually <10% of the tumor) was identified in 
41 cases, there was only one case that showed predominant papil-
lary growth (>50%) and this patient has been alive for more than 
5 years since surgical resection and without disease recurrence.
Because of this lack of clear prognostic significance for 
histologic subtyping, we focused our attention to patterns of 
invasion and nuclear grading. Using an optimal cut-point of 
10 buds/one HPF, the 5-year OS of patients with a high grade 
(≥10 buds/one HPF) for maximum tumor budding was sig-
nificantly worse (n = 76; 39%) than those with a low grade 
(<10 buds/one HPF; n = 409; 62%; p < 0.001; Fig. 4A). Using 
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an optimal cut-point of eight buds/10 HPFs, the 5-year OS 
of patients with high grade (greater than or equal to eight 
buds/10 HPFs) for total tumor budding was significantly 
worse (n = 181; 46%) than those with a low grade (less than 
eight buds/10 HPFs; n = 304; 67%; p = 0.007; Fig. 4B). 
The 5-year OS of patients with single cell invasion in the 
entire tumor was significantly worse (n = 197; 47%) than 
those without single cell invasion (n = 288; 67%; p = 0.002; 
Fig. 4C). Similarly, the 5-year OS of patients with single cell 
invasion in the tumor edge was significantly worse (n = 134; 
42%) than those without single cell invasion (n = 351; 65%; 
p = 0.001; Fig. 4D).
The presence of pleural invasion (p = 0.002; Fig. 3B) 
and lymphovascular invasion (p = 0.031; Fig. 3C) were also 
associated with a worse OS on univariate analysis. However, 
tumor differentiation (p = 0.98), tumor necrosis (p = 0.72), 
and fibrosis (p = 0.85) did not correlate with OS.
Using an optimal cut-point of four small lymphocytes 
(Fig. 2D) for nuclear diameter, the 5-year OS of patients 
with large nuclei (greater than four small lymphocytes) was 
significantly worse (n = 153; 50%) than those with small 
nuclei (n = 332; 63%; p = 0.011; Fig. 5). A higher degree of 
nuclear atypia and low mitotic count (using an optimal cut-
point of 15/10 HPF) often resulted in a worse OS. However, 
these findings were not statistically significant (p = 0.050 
and p = 0.070, respectively). Features that were not associ-
ated with OS in this cohort were N/C ratio (p = 0.20), chro-
matin pattern (p = 0.73), prominence of nucleoli (p = 0.46), 
nuclear inclusions (p = 0.89), atypical mitoses (p = 0.50), 
and Ki-67 labeling index (using an optimal cut-point of 
20%, p = 0.26).
Histological and Nuclear Features and 
Their Associations with Recurrence
Tables 2B and 3B summarize the associations between 
histological and nuclear features and the risk of recurrence. 
In the CIR analysis of stage I disease subgroup, whereas lym-
phovascular invasion was associated with an increased risk of 
TABLE 1.  Patient Characteristics and Their Associations with Patient’s Outcomes
A. Overall Survival in All Stages B. Risk of Recurrence in Stage I
Variables N (%) 5-Year OSa p Variables N (%) 5-Year CIRb p
Age, years <0.001c Age, years 0.19
  ≤65 119 25 68%   ≤65 61 22 16%
  >65 366 75 56%   >65 220 78 24%
Sex 0.049c Sex 0.008
  Female 200 41 65%  Female 124 44 16%
  Male 285 59 55%  Male 157 56 26%
Smoking pack-year 0.011c Smoking pack-year 0.071
  ≤90 397 82 61%   ≤90 225 80 20%
  >90 88 18 48%   >90 56 20 29%
Surgery 0.016c Surgery 0.44
  Lobectomy 403 83 60%  Lobectomy 213 76 23%
  Limited resection 82 17 54%   Limited resection 68 24 17%
Adjuvant therapy 0.029c Adjuvant therapy
  No 391 81 59%  No 266 95 21% 0.55
  Yes 94 19 57%  Yes 15 5 27%
T classification <0.001 T classification 0.029
  T1 213 44 67%   T1 169 60 18%
  T2 211 44 56%   T2 112 40 27%
  T3 52 11 38%   T3
Not applicable
  T4 9 2 22%   T4
N classification 0.001 N classification
Not applicable
  N0 349 72 63%   N0
  N1 87 18 50%   N1
  N2 49 10 44%   N2
Pathological stage <0.001 Pathological stage
Not applicable
  Stage I 281 58 67%   Stage I
  Stage II 136 28 51%   Stage II
  Stage III 68 14 40%   Stage III
aOS, overall survival represents percentage of patients who did not die.
bCIR, cumulative incidence of recurrence represents percentage of patients who had a recurrence.
cp values stratified by pathologic stage. Significant p values are shown in bold.
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recurrence (p = 0.041), severe fibrosis was associated with a 
reduced risk of recurrence (p = 0.019).
Multivariate Analysis of OS and Recurrence
Because there was a strong association between tumor bud-
ding (maximum and total) and single cell invasion (entire tumor 
and tumor edge), we built four multivariate OS models in which 
each of these variables were included separately. In each multivar-
iate model, high grade for maximum budding (≥10 buds /1 HPF/
one HPF; Hazard ratio [HR] = 1.04; p = 0.014), high grade for 
total tumor budding (greater than eight buds/one HPF/10 HPFs; 
HR = 1.04; p = 0.029), single cell invasion in the entire tumor 
(HR = 1.47; p = 0.003), and single cell invasion at the tumor edge 
(HR = 1.49; p = 0.004) were independent prognostic factors of 
worse OS. In addition, having large nuclei was an independent 
prognostic factor of OS in all the multivariate models (HR between 
1.09 and 1.33, p = 0.028–0.039 in the four models). Table 4 pres-
ents two models that include maximum tumor budding (Table 4A) 
and single cell invasion in entire tumor (Table 4B), respectively.
In the subgroup analysis of stage I disease, severe fibro-
sis within the tumor stroma was an independent predictor of 
a reduced risk of recurrence (severe versus mild; HR = 0.98; 
95% confidence interval (CI) = 0.95–0.99; p = 0.030) after 
adjusting for sex (male versus female; HR = 1.80; 95% 
CI = 1.04–3.13; p = 0.037) and tumor classification (T2 versus 
T1; HR = 1.55; 95% CI = 0.95–2.54; p = 0.082). However, the 
magnitude of the effect of fibrosis was small.
Associations Between Prognostic 
Histological or Nuclear Features and 
Other Clinicopathological Factors
Table 5 provides a summarization of all of the associa-
tions between the prognostic histological/nuclear features and 
the other clinicopathological factors. Tumor budding (maximum 
and total) and single cell invasion (entire tumor and tumor edge) 
were associated with larger tumor size, higher tumor stage, pres-
ence of nodal metastasis, higher pathological stage, lymphovas-
cular invasion, and pleural invasion (p < 0.05 for each analysis). 
The presence of large nuclei were associated with larger tumor 
size (p = 0.027) and lymphovascular invasion (p = 0.040).
DISCUSSION
We have performed a series of comprehensive patho-
logical analyses in an effort to identify prognostic indicators 
FIGURE 3.  Overall survival (OS) by pathological stage, pleural invasion, and lymphovascular invasion. A, The 5-year OS was 
the worst for patients with stage III disease, followed by patients with stage II and stage I disease (40%, 51%, and 67%, respec-
tively; p < 0.001). (B) The 5-year OS of patients with pleural invasion was significantly worse (n = 80; 42%) than those without 
pleural invasion (n = 405; 62%; p = 0.002). (C) The 5-year OS of patients with lymphovascular invasion was significantly worse 
(n = 332; 53%) than those without lymphovascular invasion (n = 153; 71%; p = 0.031).
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of death and recurrence in patients with resected lung squa-
mous cell carcinomas. We have demonstrated that single 
cell invasion (entire tumor and tumor edge), large nuclear 
size, and tumor budding (maximum/one HPF and total/10 
HPFs) were independently associated with an unfavorable 
OS. This contrasts with histologic subtyping, which did 
not show prognostic significance according to keratinizing, 
nonkeratinizing, clear cell, and basaloid patterns. In the 
absence of prognostic significance for histologic subtyp-
ing, we found it of interest to explore why the patterns of 
tumor invasion and nuclear grading correlated with clinical 
outcome.
Tumor budding is a relatively recently recognized mor-
phologic pattern of tumor invasion that has been shown to be 
a poor prognostic factor in colorectal cancer.9,10 Moreover, 
tumor budding has also been identified as an unfavorable 
TABLE 2.  Histologic Features and Their Associations with Patient’s Outcomes
A. Overall Survival in All Stages B. Risk of Recurrence in Stage I
Variables N (%) 5-Year OSa p Variables N (%) 5-Year CIRb p
Tumor differentiation 0.98c Tumor differentiation 0.6
  Well 56 12 58%   Well 34 12 27%
  Moderately 196 40 58%   Moderately 120 43 21%
  Poorly 233 48 60%   Poorly 127 45 21%
Keratinization 0.97c Keratinization 0.19
  Nonkeratinizing 363 75 59%   Nonkeratinizing 211 75 22%
  Keratinizing 122 25 58%   Keratinizing 70 25 32%
Basaloid pattern 0.071c Basaloid pattern 0.73
  Nonbasaloid 452 93 58%   Nonbasaloid 257 91 22%
  Basaloid 33 7 69%   Basaloid 24 9 17%
Clear cell feature 0.23c Clear cell feature 0.73
  Absence 424 87 58%   Absence 253 90 22%
  Presence 61 13 63%   Presence 28 10 20%
Tumor budding (max) <0.001c Tumor budding (max) 0.75
  Low (<10/1 HPF) 409 84 62%   Low (<10/1 HPF) 252 90 22%
  High (≥10/1 HPF) 76 16 39%   High (≥10/1 HPF) 29 10 22%
Tumor budding (total) 0.007c Tumor budding (total) 0.12
  Low (<eight/10 
HPFs)
304 63 67%   Low (<eight/10 
HPFs)
206 73 22%
  High (≥ eight/10 
HPFs)
181 37 46%   High (≥ eight/10 
HPFs)
75 27 31%
Single cell inv. (entire) 0.002c Single cell inv. (entire) 0.84
  Absent 288 59 67%   Absent 190 68 21%
  Present 197 41 47%   Present 91 32 23%
Single cell inv. (edge) 0.001c Single cell inv. (edge) 0.95
  Absent 351 72 65%   Absent 226 80 22%
  Present 134 28 42%   Present 55 20 21%
Pleural inv. 0.002c Pleural inv. 0.13
  Absent (PL0) 405 84 62%   Absent (PL0) 254 90 20%
  Present (PL1-3) 80 16 42%   Present (PL1-3) 27 10 35%
Lymphovascular inv. 0.031c Lymphovascular inv. 0.041
  Absent 153 32 71%   Absent 134 48 17%
  Present 332 68 53%   Present 147 52 26%
Necrosis 0.72c Necrosis 0.65
  Absent 190 39 63%   Absent 120 43 21%
  Present 295 61 56%   Present 161 57 23%
Fibrosis 0.85c Fibrosis 0.019
  Mild 403 83 60%   Mild 244 87 24%
  Severe 82 17 53%   Severe 37 13 8%
aOS, overall survival represents percentage of patients who did not die.
bCIR, cumulative incidence of recurrence represents percentage of patients who had a recurrence.
cp values stratified by pathologic stage. Significant p values are shown in bold.
HPF, high-power field.
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prognostic indicator in lung squamous cell carcinomas and 
adenocarcinomas.12,13,36 In a previous study on tumor bud-
ding in lung squamous cell carcinomas, the total number of 
tumor budding was counted using one HPF at ×200 magnifi-
cation.12 Using a maximal budding intensity, the presence of 
tumor budding (greater than or equal to one buds/one HPF) 
was identified as an independent prognostic factor.12 In our 
study, we used the same method to count tumor budding 
and that tumors with greater than or equal to 10 buds/one 
HPF was an independent prognostic factors for worse sur-
vival. However, the magnitude of the effect was very small 
(HR = 1.04), which suggests that, despite statistical signifi-
cance, the clinical value might be limited. A generally agreed 
cutoff for tumor budding has not yet been established for 
lung squamous cell carcinomas, and this awaits further vali-
dation studies. When counting the number of tumor budding 
using the one HPF approach, interobserver agreement could 
be problematic because of the improbability of different 
pathologists selecting the field with maximal intensity of 
tumor budding. In our study, the total number of tumor bud-
ding counted when using the 10 HPFs scoring method was 
also an independent prognostic factor. We propose that the 
10 HPFs scoring system for tumor budding is a reliable and 
reproducible method, similar to a recent proposal in colon 
carcinoma.9 In addition, this method could easily be used by 
pathologists in their clinical practice.
With regard to the size of the smallest tumor nest, our 
study demonstrated that single cell invasion (in both the entire 
tumor and the tumor edge) was an independent prognostic fac-
tor. These data were also supported by comparable findings 
in a previous study from Japan.8 The presence of small tumor 
clusters composed of less than or equal to 15 tumor cells has 
TABLE 3.  Nuclear Features and Their Associations with Patient’s Outcomes
A. Overall Survival in All Stages B. Risk of Recurrence in Stage I
Variables N (%) 5-Year OSa p Variables N (%) 5-year CIRb p
Nuclear diameter 0.011c Nuclear diameter 0.26
  Small 332 68 63%   Small 198 70 21%
  Large 153 32 50%   Large 83 30 24%
Nuclear atypia 0.050c Nuclear atypia 0.71
  Mild 78 16 67%   Mild 59 21 25%
  Moderate 275 57 61%   Moderate 154 55 21%
  Severe 132 27 49%   Severe 68 24 21%
Nuclear/cytoplasmic ratio 0.20c Nuclear/cytoplasmic ratio 0.24
  Low 61 13 65%   Low 38 14 12%
  Intermediate 310 64 56%   Intermediate 177 63 24%
  High 114 24 63%   High 66 23 22%
Chromatin pattern 0.73c Chromatin pattern 0.64
  Fine 198 41 65%   Fine 145 52 21%
  Coarse 287 59 54%   Coarse 136 48 23%
Prominence of nucleoli 0.46c Prominence of nucleoli 0.69
  Indistinct 340 70 62%   Indistinct 202 72 21%
  Distinct 145 30 52%   Distinct 79 28 23%
Nuclear inclusion 0.89c Nuclear inclusion
  Absent 475 98 59% Absent 276 98 22% 0.2
  Present 10 2 40% Present 5 2 0%
Mitotic count 0.070c Mitotic count 0.84
  Low (<15/10 
HPFs)
147 30 56%   <15/10 HPFs 98 35 24%
  High (≥15/10 HPFs) 338 70 60%   ≥15/10 HPFs 183 65 21%
Atypical mitosis 0.50c Atypical mitosis 0.18
  Absent 149 31 60%   Absent 95 34 19%
  Present 336 69 58%   Present 186 66 23%
Ki-67 labeling index 0.26c Ki-67 labeling index 0.39
  Low (<20%) 47 11 66%   Low (<20%) 31 12 17%
  High (≥20%) 400 89 57%   High (≥20%) 220 88 23%
aOS, overall survival represents percentage of patients who did not die.
bCIR, cumulative incidence of recurrence represents percentage of patients who had a recurrence.
cp values stratified by pathologic stage. Significant p values are shown in bold.
HPF, high-power field.
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previously been used as a histologic risk model in head and 
neck squamous cell carcinomas,14,15 but this approach did not 
prove to be a prognostic indicator in our study on lung squa-
mous cell carcinoma.
Published data on the prognosis of basaloid carcinomas 
is conflicting. Basaloid carcinomas are a rare subtype of lung 
cancer with a reported incidence of 6% of NSCLCs.27 In the 
1999 and 2004 WHO classifications, basaloid carcinomas were 
included as a variant of large cell carcinomas and squamous 
cell carcinomas.7 In the past classifications, basaloid variant 
was described as the tumor having prominent peripheral pali-
sading of tumor cells with scanty cytoplasm and hyperchro-
matic nuclei; however, the percentage cutoff for basaloid patter 
was not defined to classify the tumors as basaloid subtype.7,26 
In the upcoming revision of the WHO classification, all squa-
mous cell carcinomas with a basaloid component greater than 
50% will be considered as basaloid subtype of squamous cell 
carcinoma, and pure tumors will no longer be variants of large 
cell carcinoma. Moreover, nonbasaloid squamous cell car-
cinomas (tumors with no or less than 50% basaloid pattern) 
will be classified into keratinizing or nonkeratinizing subtype 
using a similar definition to nasopharyngeal carcinomas in the 
2005 WHO Classification, Pathology and genetics of Head 
FIGURE 4.  Overall survival (OS) by tumor budding and single cell invasion. A, The 5-year OS of patients with high grade  
(≥10 buds/one high-power fields [HPF]) for maximum budding was significantly worse (n = 76; 39%) than those with low grade 
(<10 buds/one HPF; n = 409; 62%; p < 0.001). (B) The 5-year OS of patients with high grade (greater than or equal to eight 
buds/10 HPFs) for total tumor budding was significantly worse (n = 181; 46%) than those with low grade (less than eight buds/10 
HPFs; n = 304; 67%; p = 0.007). (C) The 5-year OS of patients with single cell invasion in entire tumor was significantly worse  
(n = 197; 47%) than those without single cell invasion (n = 288; 67%; p = 0.002). (D) The 5-year OS of patients with single cell 
invasion in tumor edge was significantly worse (n = 134; 42%) than those without single cell invasion (n = 351; 65%; p = 0.001).
FIGURE 5.  Overall survival (OS) by nuclear diameter. The 
5-year OS of patients with large nuclei (greater than four 
small lymphocytes) was significantly worse (n = 153; 50%) 
than those with small nuclei (n = 332; 63%; p = 0.011).
1135Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 8, August 2014 Pathology Analyses in Lung Squamous Cell Carcinoma
and Neck Tumors.25 Several studies have reported that basaloid 
carcinomas (including basaloid squamous cell carcinomas and 
basaloid large cell carcinomas) had a shorter patient survival 
than nonbasaloid squamous cell carcinomas.27,37 Conversely, 
there are studies from East Asian countries that have reported 
no statistical difference in survival between patients with basa-
loid squamous cell carcinomas and those with poorly differ-
entiated, nonbasaloid squamous cell carcinomas.38,39 In our 
study of patients from the United States, patients with basaloid 
squamous cell carcinomas had a trend for better prognosis than 
those with nonbasaloid tumors, although the finding was not 
statistically significant. These differences in the prognosis of 
basaloid squamous cell carcinomas between the studies may be 
due to variations in disease stage, the histologic type of basa-
loid tumors (including basaloid NSCLCs, basaloid squamous 
cell carcinomas, or basaloid large cell carcinomas), treatment 
modalities, ethnic differences, genetic differences, or interob-
server agreement in identifying basaloid patterns. The prog-
nostic significance and reproducibility of the basaloid subtype 
in lung squamous cell carcinomas is still controversial and fur-
ther investigation is required.
Our data have potential implications for the upcom-
ing revision of the WHO classification. Similar to previous 
studies, the degree of keratinization, including the presence 
of keratinization and tumor differentiation, was not associated 
with prognosis.8,40 However, keratinizing and nonkeratiniz-
ing subtypes of squamous cell carcinoma are well-established 
subtypes in sites like the nasopharynx where they are part of 
the WHO Classification, despite the lack of clear prognos-
tic importance..25 Recognizing a nonkeratinizing subtype of 
squamous cell carcinoma in the lung is also important because 
these tumors can have morphologic overlap with pseudosqua-
mous adenocarcinomas. This distinction has molecular and 
therapeutic implications, and so accurate diagnosis requires 
immunohistochemistry for adenocarcinoma and squamous 
markers such as TTF-1 and p40, respectively.41 To the best of 
our knowledge, the prognostic significance of clear cell fea-
tures in lung squamous cell carcinomas is unknown, and there 
was no prognostic value in our study. This combined with 
the infrequency of clear cell predominant features is against 
maintaining clear cell as a major subtype of squamous cell 
carcinoma.
The papillary variant of lung squamous cell carcinomas 
can show exophytic and endobronchial growth, but most cases 
show submucosal or bronchial wall invasion.42 Even though it 
has been reported that tumors were almost always recognized 
in early stages (mainly T1N0) and that the prognosis is not any 
better than other stage I lung cancers, the prognostic signifi-
cance of the papillary subtype is still unknown.42 The papillary 
subtype of lung squamous cell carcinoma is extremely rare, 
and there was only one case in our cohort of 485 patients that 
exhibited predominant papillary growth. The rarity of papil-
lary predominant squamous cell carcinomas and the lack of 
clear prognostic importance provide good reasons to question 
whether it should be a major subtype of squamous cell car-
cinoma in the WHO classification. The “small cell” subtype 
of squamous cell carcinoma included in the 1999 and 2004 
WHO classifications is no longer accepted as these tumors 
most likely represented basaloid carcinomas with very small 
tumor cell size and because the term “small cell” could lead to 
TABLE 4.  Multivariate Analysis of Overall Survival in All Stages (n = 485)
A. Model for Tumor Budding (Maximum/One HPF) HR 95% CI p
Age > 65 vs. ≤ 65 1.72 1.26–2.36 <0.001
Sex Male vs. female 1.24 0.96–1.59 0.096
Smoking pack-year >90 vs. ≤90 1.25 0.92–1.70 0.15
Surgery Lobectomy vs. limited resection 1.3 0.93–1.80 0.12
Pathological stage II vs. I 1.38 1.02–1.87 0.037
III vs. I 2.18 1.51–3.15 <0.001
Lymphovascular inv. Present vs. absent 1.25 0.92–1.70 0.15
Tumor budding (maximum) High (≥10/HPF) vs. low (<10/HPF) 1.04 1.01–1.07 0.014
Nuclear diameter Large vs. small 1.33 1.03–1.70 0.028
B. Model for single cell invasion (entire tumor) HR 95% CI p
Age > 65 vs. ≤ 65 1.89 1.37–2.59 <0.001
Sex Male vs. female 1.22 0.95–1.57 0.11
Smoking pack-year >90 vs. ≤90 1.26 0.93–1.70 0.14
Surgery Lobectomy vs. limited resection 1.35 0.97–1.88 0.074
Pathological stage II vs. I 1.43 1.05–1.93 0.021
III vs. I 2.2 1.52–3.18 <0.001
Lymphovascular inv. Present vs. absent 1.21 0.89–1.64 0.23
Single cell inv. (entire tumor) Present vs. absent 1.47 1.14–1.88 0.003
Nuclear diameter Large vs. small 1.3 1.01–1.68 0.039
Significant p values are shown in bold.
HR, hazard ratio; CI, confidence interval; HPF, high-power field
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clinical confusion with diagnosis of small cell carcinoma.7,26,43 
given these considerations the upcoming revision of the WHO 
classification for subclassification of squamous cell carcinoma 
includes keratinizing, nonkeratinizing, and basaloid subtypes.
The clinical utility of a nuclear grading system that 
includes nuclear atypia and mitotic count has already been 
established in other carcinomas, such as breast, kidney, and 
bladder.16,17,44–46 Although our group and others have demon-
strated the prognostic value of nuclear grades in lung adeno-
carcinomas,18,21,47,48 the prognostic utility of nuclear grade 
remains unknown in lung squamous cell carcinomas. In our 
study, large nuclei, which is defined as greater than four small 
lymphocytes in nuclear diameter, was independently associ-
ated with a worse OS; this was done after stratifying by patho-
logic stage. Although there was a trend of worse prognosis in 
those with severe atypia, nuclear atypia was not statistically 
significant for predicting prognosis. Therefore, we believe that 
nuclear diameter might be a more reliable factor associated 
with clinical outcome. It could provide greater reproducibil-
ity by use of a semiquantitative method that measures nuclear 
diameter with a small lymphocyte. In contrast to the unfavor-
able prognostic value of a higher mitotic count in lung adeno-
carcinomas,21,47,48 our study of lung squamous cell carcinomas 
showed that patients with a higher mitotic count often had 
better prognoses. This similar finding was also reached in a 
previous study.49 A higher mitotic count may have a differ-
ent prognostic and biological relevance in lung squamous cell 
carcinomas than it does in lung adenocarcinomas. In addition 
to mitotic count, a high Ki-67 proliferation index was also 
reported to be a poor prognostic marker in lung adenocarcino-
mas and NSCLCs by our group and others.21,50,51 However, we 
did not identify any prognostic value in the Ki-67 proliferation 
index in our lung squamous cell carcinoma cohort.
In multivariate analysis of OS adjusting for clinical 
and pathological factors (including pathologic stage and lym-
phovascular invasion), which were significantly prognostic 
TABLE 5.  Associations Between Clinicopathologic Characteristics and Prognostic Pathological Factors
Variables
Tumor Budding 
(Maximum/One HPF)
Tumor Budding 
(Total/10 HPFs)
Single Cell Invasion 
(Entire Tumor)
Single Cell Invasion 
(Tumor Edge) Nuclear Diameter
Low High p Low High P Absent Present p Absent Present p Small Large p
Age, years 0.098 0.059 0.033 0.16 0.14
  Median 71 74 72 70 72 70 71 71 71 73
  Range 42–88 39–87 42–88 39–87 44–88 38–87 42–88 39–87 39–88 42–88
Sex 0.77 0.081 0.15 0.015 0.75
  Female 41% 43% 44% 36% 44% 37% 45% 32% 42% 40%
  Male 59% 57% 56% 64% 56% 63% 55% 68% 58% 60%
Smoking pack-year 0.74 0.39 0.51 0.79 0.092
  Median 53 52 51 53 50 54 54 51 50 59
  Range 0–180 0–252 0–180 0–252 0–180 0–252 0–180 0–252 0–180 5–252
Tumor size 0.006 <0.001 <0.001 <0.001 0.027
  Median 3 3.8 2.6 4 2.6 3.8 2.8 4 3 3.5
  Range 0.5–14 1.3–17 0.5–14 1.2–17 0.5–14 1.2–17 0.5–14 1.4–17 0.5–17 0.9–14
Tumor stage <0.001 <0.001 <0.001 <0.001 0.51
  T1 + T2 90% 71% 93% 78% 92% 80% 93% 74% 88% 86%
  T3 + T4 10% 29% 7% 22% 8% 20% 7% 26% 12% 14%
Nodal stage 0.046 <0.001 0.02 <0.001 0.93
  N0 74% 62% 77% 63% 76% 66% 75% 63% 72% 73%
  N1 + N2 26% 38% 23% 37% 24% 34% 25% 37% 28% 27%
Pathologic stage <0.001 <0.001 <0.001 0.007 0.31
  Stage I 62% 38% 68% 41% 66% 46% 64% 41% 60% 54%
  Stage II 
+ III
38% 62% 32% 59% 34% 54% 36% 59% 40% 46%
Lymphovascular inv. <0.001 <0.001 <0.001 <0.001 0.04
  Absent 36% 5% 43% 12% 42% 16% 39% 12% 35% 25%
  Present 64% 95% 57% 88% 58% 84% 61% 88% 65% 75%
Pleural inv. <0.001 <0.001 <0.001 <0.001 0.056
  Absent 
(PL0)
88% 62% 91% 71% 90% 74% 89% 69% 86% 78%
  Present 
(PL123)
12% 38% 9% 29% 10% 26% 11% 31% 14% 22%
Significant p values are shown in bold.
HPF, high-power field
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in univariate analyses, maximum budding (HR = 1.04), total 
tumor budding (HR = 1.04), single cell invasion in the entire 
tumor (HR = 1.47), and single cell invasion in the tumor edge 
(HR = 1.49) were found to be independent prognostic factors 
for worse outcomes. However, these aggressive invasive pat-
terns (tumor budding and single cell invasion) were signifi-
cantly associated with other strong prognostic factors (such as 
pathologic stage and lymphovascular invasion), and the HRs 
close to one for these invasive patterns suggest limited clini-
cal utility (especially for tumor budding variables). Therefore, 
further validation studies are warranted to confirm indepen-
dent prognostic impact in these factors.
Tumor necrosis has been proposed as a prognostic factor 
that should be included in the grading system for renal cell car-
cinomas.52,53 In a previous study, our group demonstrated that 
the presence of tumor necrosis was an independent predictor 
of a higher risk of recurrence in stage I lung adenocarcino-
mas.21 In our current study on lung squamous cell carcinoma, 
however, tumor necrosis was not associated with patient’s out-
comes, although the 5-year OS of patients with tumor necrosis 
was slightly worse (56%) than those without necrosis (63%). 
Prominent fibrous stroma in tumors has been reported as a 
poor prognostic factor in squamous cell carcinomas of the lung 
and esophagus.29,40 Nevertheless, in our study of lung squa-
mous cell carcinomas, severe intratumoral stromal fibrosis 
was not associated with OS. Conversely, severe intratumoral 
stromal fibrosis did independently correlate with a reduced 
risk of recurrence in patients with stage I disease. These dif-
ferences in the prognostic value of tumor fibrosis between the 
studies might be due to variations in tumor locations (lung ver-
sus esophagus), definitions for severe fibrosis, endpoints for 
prognostic analyses (survival versus recurrence), or the ethnic 
groups of patients. In addition, HR for fibrosis in predicting 
disease recurrence is close to 1.00 (actual HR = 0.98) and 
does not have strong impact even if it is statistically significant 
(p = 0.030). Therefore, this finding warrants further investiga-
tion using more uniform cohorts and methods.
One of the criticisms of microscopic analysis is that 
there can be interobserver variability in evaluating histologi-
cal and nuclear features. Therefore, standardized definitions 
are necessary for a pathologic factor especially if it has a 
prognostic impact. However, in the current WHO classifica-
tion for lung squamous cell carcinoma, there are no standard-
ized definitions (e.g., % cutoffs of each histologic pattern) for 
classifying tumors into histologic subtypes, such as basaloid 
pattern and clear cell feature.7 In lung squamous cell carci-
noma, furthermore, tumor grade based on degree of squamous 
differentiation (keratinization) has no standardized cutoff 
for distribution (%) of differentiated area in each category 
(well, moderately, and poorly differentiated). In this study, 
we recorded the distribution (%) of each histologic feature in 
5% increments (such as keratinization, basaloid pattern, clear 
cell feature, tumor necrosis, and fibrosis) and used small lym-
phocytes to evaluate nuclear diameter. Similarly, in the 2011 
IASLC/ATS/ERS classification, histologic subtyping is rec-
ommended to be recorded in in 5% increments.2 According 
to this recommendation, prognostic impact of predominant 
histologic subtypes has been validated in independent large 
cohorts.3–6 In addition, this method provided good reproduc-
ibility (kappa score: 0.77 ± 0.07) in identifying predominant 
histologic subtypes based on an international interobserver 
study.54 As used in our previous study for lung adenocarci-
noma,18 we measured nuclear diameter using small lympho-
cytes in this study for lung squamous cell carcinoma. This 
method was originally described by Nakazato et al.19,55 with 
prognostic significance of nuclear diameter and moderate to 
good reproducibility (kappa score: 0.58 ± 0.09) in measuring 
it by small lymphocytes in lung adenocarcinoma.
In conclusion, we have addressed the prognostic impor-
tance of histologic subtyping as well as single cell invasion, 
nuclear diameter, and tumor budding. These histological fea-
tures were analyzed using a large patient cohort who under-
went resection of squamous cell carcinomas of the lung and 
with respect to OS and CIR. We discovered that the traditional 
2004 WHO histologic subtyping and grading system that was 
based on the degree of keratinization were not prognostically 
significant factors. Because morphological assessment using 
H&E-stained slides is utilized in routine clinical practice for 
resected lung carcinomas, our findings can be validated in dif-
ferent datasets. Therefore, to establish a prognostic grading 
system for patients with lung squamous cell carcinomas based 
on the prognostic pathological factors we reported here, our 
results should be validated in a series of independent cohorts, 
and consistent interobserver agreement should be ensured by 
using uniform methods. If our findings can be confirmed, they 
may help clinical management of patients with lung squamous 
cell carcinomas and stratify patients for adjuvant therapy.
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